FibroGen
Judy Whitten has extensive experience in clinical finance, currently serving as Senior Manager of Clinical Finance at FibroGen since April 2013. Prior to this role, Judy held positions such as Associate Manager of Clinical Finance at Gilead Sciences and Sr. Financial Analyst at Genentech, where responsibilities included managing monthly accruals, budget forecasting, and billing projects within the Pharmaceutical Technical Operations Contract Manufacturing Organization. Judy's earlier experience includes serving as Sr. Financial Analyst at Poniard Pharmaceuticals and Financial Analyst at Franklin Templeton. Judy holds an MBA from Notre Dame de Namur University and a Bachelor of Science in Accounting and Business/Management from San Francisco State University.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.